BD (Becton, Dickinson and Company) announced Peter Menziuso as the new executive vice president and president of BD Interventional, effective June 1, 2026. Menziuso brings over 30 years of global healthcare leadership, previously leading a $5 billion business at Johnson & Johnson Vision. His experience in commercial operations, R&D, and operational excellence is expected to accelerate growth and strengthen BD Interventional’s market position. BD aims to continue delivering strong performance and innovation in medical technology under his leadership.
The global enteric disease testing market is projected to grow from $4.08 billion in 2025 to $5.86 billion by 2035, at a CAGR of 3.7%. Growth is fueled by rising foodborne and waterborne diseases, demand for rapid pathogen detection, and adoption of ...
BD (Becton, Dickinson and Company) announced its BD® CentroVena One™ Insertion System received an Innovative Technology contract from Vizient, recognizing its breakthrough design that simplifies central line insertion and enhances patient and clinici...
Representative Thomas H. Kean Jr., a New Jersey Republican on the House Energy and Commerce Committee, disclosed four recent stock trades through the Kean Family Partnership. He bought shares in Amcor plc and EQT Corporation, while selling shares in ...
The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...
